Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence

References

• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNNational Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart AssociationImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• RobinsonJGManagement of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacinVasc Health Risk Manag200951314319436666
   PubMedGoogle Scholar
• British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke AssociationJBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practiceHeart200591Suppl 5v1v5216365341
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean Society of Cardiology (ESC) Committee for Practice Guidelines (CPG)European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)Eur Heart J200728192375241417726041
   PubMed Web of Science ®Google Scholar
• ChapmanMJGinsbergHNAmarencoPEuropean Atherosclerosis Society Consensus PanelTriglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementEur Heart J201132111345136121531743
   PubMed Web of Science ®Google Scholar
• BirjmohunRSHuttenBAKasteleinJJStroesESEfficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trialsJ Am Coll Cardiol200545218519715653014
   PubMed Web of Science ®Google Scholar
• BruckertELabreucheJAmarencoPMeta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosisAtherosclerosis2010210235336120079494
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial resultsI. Reduction in incidence of coronary heart diseaseJAMA198425133513646361299
   PubMed Web of Science ®Google Scholar
• WattsGFLewisBBruntJNEffects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS)Lancet199233987935635691347091
   PubMed Web of Science ®Google Scholar
• BruckertELabreucheJDeplanqueDTouboulPJAmarencoPFibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysisJ Cardiovasc Pharmacol201157226727221052016
   PubMed Web of Science ®Google Scholar
• BrielMFerreira-GonzalezIYouJJAssociation between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysisBMJ2009338b9219221140
   PubMed Web of Science ®Google Scholar
• LabreucheJDeplanqueDTouboulPJBruckertEAmarencoPAssociation between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and metaregression analysisAtherosclerosis2010212191520457452
   PubMed Web of Science ®Google Scholar
• BrownBGStukovskyKHZhaoXQSimultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trialsCurr Opin Lipidol200617663163617095907
   PubMed Web of Science ®Google Scholar
• GouldALRossouwJESantanelloNCHeyseJFFurbergCDCholesterol reduction yields clinical benefit: impact of statin trialsCirculation199897109469529529261
   PubMed Web of Science ®Google Scholar
• EdwardsJEMooreRAStatins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trialsBMC Fam Pract200341814969594
   PubMedGoogle Scholar
• GouldALDaviesGMAlemaoEYinDDCookJRCholesterol reduction yields clinical benefits: meta-analysis including recent trialsClin Ther200729577879417697899
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA2002288232998300712479764
   PubMed Web of Science ®Google Scholar
• AmarencoPBogousslavskyJCallahanAStroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) InvestigatorsHigh-dose atorvastatin after stroke or transient ischemic attackN Engl J Med2006355654955916899775
   PubMed Web of Science ®Google Scholar
• KasteleinJJAkdimFStroesESENHANCE InvestigatorsSimvastatin with or without ezetimibe in familial hypercholesterolemiaN Engl J Med2008358141431144318376000
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS investigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPFIELD study investigatorsEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536695001849186116310551
   PubMed Web of Science ®Google Scholar
• BoschJGersteinHCDagenaisGRORIGIN Trial Investigatorsn-3 fatty acids and cardiovascular outcomes in patients with dysglycemiaN Engl J Med2012367430931822686415
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCACCORD Study GroupEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• KoizumiJShimizuMMiyamotoSOrigasaHMabuchiHEffect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT)J Atheroscler Thromb20029525125912409635
   PubMedGoogle Scholar
• ShepherdJBlauwGJMurphyMBPROSPER study groupPROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236093461623163012457784
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA199827920161516229613910
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRASCOT investigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• ManninenVEloMOFrickMHLipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart StudyJAMA198826056416513164788
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAJUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• CrouseJRRaichlenJSRileyWAMETEOR Study GroupEffect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR TrialJAMA2007297121344135317384434
   PubMed Web of Science ®Google Scholar
• NakamuraHArakawaKItakuraHMEGA Study GroupPrimary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trialLancet200636895421155116317011942
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med199533320130113077566020
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• WhitneyEJKrasuskiRAPersoniusBEA randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical eventsAnn Intern Med200514229510415657157
   PubMed Web of Science ®Google Scholar
• BodenWEProbstfieldJLAndersonTAIM-HIGH InvestigatorsNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• KorenMJHunninghakeDBALLIANCE InvestigatorsClinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance studyJ Am Coll Cardiol20044491772177915519006
   PubMed Web of Science ®Google Scholar
• de LemosJABlazingMAWiviottSDInvestigatorsEarly intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJAMA2004292111307131615337732
   PubMed Web of Science ®Google Scholar
• EricssonCGHamstenANilssonJGripLSvaneBde FaireUAngiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patientsLancet199634790058498538622389
   PubMed Web of Science ®Google Scholar
• GoldenbergIBenderlyMGoldbourtUBIP Study GroupSecondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trialJ Am Coll Cardiol200851445946518222357
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsN Engl J Med199633514100110098801446
   PubMed Web of Science ®Google Scholar
• Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico)Ital Heart J200011281082011302109
   PubMedGoogle Scholar
• AthyrosVGMikhailidisDPPapageorgiouAAGREACE Collaborative GroupEffect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) StudyCurr Med Res Opin200420562763715171226
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoXQChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med2001345221583159211757504
   PubMed Web of Science ®Google Scholar
• HulleySGradyDBushTRandomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research GroupJAMA199828076056139718051
   PubMed Web of Science ®Google Scholar
• FrickMHHeinonenOPHuttunenJKKoskinenPMänttäriMManninenVEfficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame populationAnn Med199325141458435186
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJIncremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study GroupHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005294192437244516287954
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupN Engl J Med199833919134913579841303
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGEzekowitzMDMyocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study InvestigatorsEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trialJAMA2001285131711171811277825
   PubMed Web of Science ®Google Scholar
• The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial InvestigatorsN Engl J Med199733631531628992351
   PubMed Web of Science ®Google Scholar
• PittBManciniGBEllisSGRosmanHSParkJSMcGovernMEPravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigationJ Am Coll Cardiol1995265113311397594023
   PubMed Web of Science ®Google Scholar
• JukemaJWBruschkeAVvan BovenAJEffects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)Circulation19959110252825407743614
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDTreating to New Targets (TNT) InvestigatorsIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341641041810438259
   PubMed Web of Science ®Google Scholar
• MorrisonAHokansonJEThe independent relationship between triglycerides and coronary heart diseaseVasc Health Risk Manag200951899519436658
   PubMedGoogle Scholar
• MillerMStoneNJBallantyneCAmerican Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular DiseaseTriglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationCirculation2011123202292233321502576
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ20033267404142312829554
   PubMed Web of Science ®Google Scholar
• DavidsonMHMcKenneyJMShearCLRevkinJHEfficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levelsJ Am Coll Cardiol20064891774178117084249
   PubMed Web of Science ®Google Scholar
• BaysHEMcKenneyJMDujovneCAGemcabene Study GroupEffectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterolAm J Cardiol200392553854312943873
   PubMed Web of Science ®Google Scholar
• WittrupHHTybjaerg-HansenANordestgaardBGLipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysisCirculation199999222901290710359734
   PubMed Web of Science ®Google Scholar
• HokansonJEFunctional variants in the lipoprotein lipase gene and risk cardiovascular diseaseCurr Opin Lipidol199910539339910554701
   PubMed Web of Science ®Google Scholar
• GagnéSELarsonMGPimstoneSNA common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring StudyClin Genet199955645045410450862
   PubMed Web of Science ®Google Scholar
• HuYLiuWHuangRZhangXA systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseasesJ Lipid Res20064791908191416741292
   PubMed Web of Science ®Google Scholar
• ThompsonADi AngelantonioESarwarNAssociation of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary riskJAMA2008299232777278818560005
   PubMed Web of Science ®Google Scholar
• SarwarNSandhuMSRickettsSLTriglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors CollaborationTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesLancet201037597261634163920452521
   PubMed Web of Science ®Google Scholar
• Frikke-SchmidtRNordestgaardBGSteneMCAssociation of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart diseaseJAMA2008299212524253218523221
   PubMed Web of Science ®Google Scholar
• Di AngelantonioESarwarNPerryPEmerging Risk Factors CollaborationMajor lipids, apolipoproteins, and risk of vascular diseaseJAMA2009302181993200019903920
   PubMed Web of Science ®Google Scholar
• SarwarNDaneshJEiriksdottirGTriglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studiesCirculation2007115445045817190864
   PubMed Web of Science ®Google Scholar